S. Fehmi KATIRCIOĞLU, Atilla KESKİN, Göknur TOROS YAPAR, Nilgün ALTI, Gülkan SOLGUN, İrfan ŞENCAN, Salih CESUR

Vankomisine Dirençli Enterococcus faecium'a Bağlı Olarak Prostetik Kapak Endokarditi Gelişen Olgu

Vankomisine dirençli enterokok (VRE) lara bağlı proste¬tik kapak endokarditi oldukça nadirdir ve sıklıkla hastanekaynaklı olarak gelişebilir. Burada, vankomisine dirençli Enterococcus faeciuma bağlı prostetik kapak endokarditigelişen 28 yaşında bir kadın olgu sunulmuş ve literatür tartışılmıştır.

A Case of Prosthetic Valve Endocarditis Due to Vancomycin-Resistant Enterococcoccus faecium

Endocarditis due to vancomycine resistant enteroccoci is very rare and it is commonly developed as an nosocomialinfection. In this manuscript, a 28 years old female who developed prostetic valve endocarditis due to vancomycinresistant Enterococcus faecium was presented and the literature was discussed.

PDF

___

1. Stevens MP, Edmond MB. Endocarditis due to vancomycin-resist- ant enterococci: case report and review of the literature. Clin Infect Dis. 2005; 41(8):1134-42.
2. LeClercq R, Erlot E, Duval J, Courvalin P. Plasmid-mediated re- sistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319(3):15761.
3. Fournier S, Brossier F, Fortineau N, Gillaizeau F, Akpabie A, Au- bry A,et al. Long-term control of vancomycin-resistant Entero- coccus faecium at the scale of a large multihospital institution: a seven-year experience. Euro Surveill. 2012; 26;17(30). pii: 20229.
4. Calfee DP. Methicillin-resistant Staphylococcus aureus and van- comycin-resistant enterococci, and other Gram-positives in health- care. Curr Opin Infect Dis. 2012 ;25(4):385-94.
5. Colak D, Naas T, Gunseren F, Fortineau N, Ogunc D, Gultekin M, Nordmann P. First outbreak of vancomycin-resistant entero- cocci in a tertiary hospital in Turkey. J Antimicrob Chemother. 2002;50(3):397-401.
6. Bishara J, Sagie A, Samra Z, Pitlik S. Polymicrobial endocarditis caused by methicillin-resistant Staphylococcus aureus and glyc- opeptide-resistant enterococci. Eur J Clin Microbiol Infect Dis 1999; 18(9):6745.
7. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001;345 (18):131830.
8. Forrest GN, Arnold RS, Gammie JS, Gilliam BL. Single center experience of a vancomycin resistant enterococcal endocarditis cohort. J Infect. 2011 ; 63 (6):420-8.
9. Tiong IY, Novaro GM, Jefferson B, Monson M, Smedira N, Penn MS.Bacterial endocarditis and functional mitral stenosis: a report of two cases and brief literature review. Chest 2002; 122(6):225962.
10. Furlong WB, Rakowski TA. Therapy with RP 59500 (quinupris- tin/ dalfopristin) for prosthetic valve endocarditis due to entero- cocci with VanA/VanB resistance patterns. Clin Infect Dis 1997; 25(1):1634.
11. Yelamanchili S, Cunliffe NA, Miles RS. Prosthetic valve endo- carditis caused by a vancomycin-resistant Enterococcus faecalis. J Infect 1998;36(3):3489.
12. Carfagna P, Tarasi A, Cassone M, Del Grosso MF, Bianco G, Ven- ditti M. Prosthetic biologic valve endocarditis caused by a vanco- mycinresistant (vanA) Enterococcus faecalis: case report. J Chem- other 2000;12(5):41620.
13. Safdar A, Bryan CS, Stinson S, Saunders DE. Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: treatment with chloramphenicol plus minocycline. Clin Infect Dis 2002; 34(11):E61-3.
14. Brink AJ, van den Ende J, Routier RJ, Devenish L. A case of van- comycin-resistant enterococcal endocarditis. S Afr Med J 2000; 90(11):11135.
15. 1Nori US, Manoharan A, Thornby JI, Yee J, Parasuraman R, Ra- manathan V. Mortality risk factors in chronic haemodialysis pa- tients with infective endocarditis. Nephrol Dial Transplant. 2006 ;21(8):2184-90.
16. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38(7): 9941000.
17. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of van- comycin-resistant Enterococcus faecium infections with quinu- pristin/dalfopristin. Clin Infect Dis 2001;33(11):181623.
18. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, grampositive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36(2):15968.
19. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Activity of daptomycin against susceptible and multidrugresistant gram-positive pathogens collected in the SE- CURE study during 20002001. J Antimicrob Chemother 2003; 51(3):63949.
20. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the Eu- ropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. European Heart Journal 2009; 30(19): 2369-2413.
21. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retro- spective case series of 31 patients. Pharmacotherapy. 2006 ;26 (3):347-52.
22. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant en- terococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009; 29(7): 792-9.
23. Reşat Ozaras, Fehmi Tabak. Daptomisin. Klimik Dergisi 2010; 23(2): 35-8
24. Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother. 2009; 64(1): 175-80.
25. Kaya S, Yilmaz G, Kalkan A, Ertunç B, Köksal I. Treatment of Gram-positive left-sided infective endocarditis with daptomycin. J Infect Chemother. 2013;41(11):1053-8.